Intellectual Property Magazine
Editor's letter October 2019
Catherine White, IPM
In October 2018, AbbVie’s EU patent for itsanti-tumour necrosis drug, adalimumab (Humira) expired, prompting commentators
to hail this as a “pivotal moment” in the evolution of the biosimilars
marketplace.